Naperville, IL -- (SBWIRE) -- 08/07/2014 -- Reportstack, provider of premium market research reports announces the addition of Targeted Drug Delivery Partnering 2009-2014 market report to its offering
Targeted Drug Delivery Partnering 2009-2014 report provides understanding and access to the targeted drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in targeted drug delivery partnering deals
Top Targeted deals by value
Deals listed by company A-Z, deal type, stage of development, therapy type
Targeted Drug Delivery Partnering 2009-2014 provides understanding and access to the targeted partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter targeted drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.
This report contains over 180 links to online copies of actual targeted drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.
The initial chapters of this report provide an orientation of targeted drug delivery dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in targeted drug delivery dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms. Chapter 2 also contains case studies providing an insight into how companies enter into targeted drug delivery dealmaking.
Chapter 3 provides a review of the leading targeted drug delivery deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of targeted drug delivery partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in targeted drug delivery partnering and dealmaking since 2009.
In conclusion, this report provides everything a prospective dealmaker needs to know about targeted drug delivery partnering in the research, development and commercialization of drug delivery technologies and products.
Targeted Drug Delivery Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to targeted drug delivery trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
Trends in targeted drug delivery dealmaking in the biopharma industry since 2009
Access to summary headline, upfront, milestone and royalty data
Access to over 130 targeted drug delivery contract documents
The leading targeted drug delivery deals by value since 2009
In Targeted Drug Delivery Partnering 2009-2014, the available deals are listed by:
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Abbott, Actavis, Watson Pharmaceuticals, Actelion, Allergan, Amgen, Aspen Pharmacare, Astellas, AstraZeneca, Pfizer, Novartis, GSK, Takeda, Bayer, Boehringer Ingelheim
To view the table of contents for this market research report please visit